Abstract LB-024: Inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1): evidence for impaired vitamin D signaling in an MMTV-PYMT mouse model of breast cancer

2019 ◽  
Author(s):  
Sylvester Jusu ◽  
John Presley ◽  
Bertrand Jean-Claude ◽  
Ursula Stochaj ◽  
Richard Kremer
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Mouse Model ◽  
Hydroxyvitamin D ◽  
Hydroxylase Gene ◽  
25 Hydroxyvitamin D ◽  
Vitamin D Signaling

scholarly journals Tumor Autonomous Effects of Vitamin D Deficiency Promote Breast Cancer Metastasis

Endocrinology ◽  
2016 ◽  
Vol 157 (4) ◽  
pp. 1341-1347 ◽  
Author(s):  
Jasmaine D. Williams ◽  
Abhishek Aggarwal ◽  
Srilatha Swami ◽  
Aruna V. Krishnan ◽  
Lijuan Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Metastasis ◽  
Receptor Expression ◽  
Inverse Association ◽  
Primary Tumors ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Vitamin D Signaling

Abstract Patients with breast cancer (BCa) frequently have preexisting vitamin D deficiency (low serum 25-hydroxyvitamin D) when their cancer develops. A number of epidemiological studies show an inverse association between BCa risk and vitamin D status in humans, although some studies have failed to find an association. In addition, several studies have reported that BCa patients with vitamin D deficiency have a more aggressive molecular phenotype and worse prognostic indicators. However, it is unknown whether this association is mechanistically causative and, if so, whether it results from systemic or tumor autonomous effects of vitamin D signaling. We found that ablation of vitamin D receptor expression within BCa cells accelerates primary tumor growth and enables the development of metastases, demonstrating a tumor autonomous effect of vitamin D signaling to suppress BCa metastases. We show that vitamin D signaling inhibits the expression of the tumor progression gene Id1, and this pathway is abrogated in vitamin D deficiency in vivo in 2 murine models of BCa. These findings are relevant to humans, because we discovered that the mechanism of VDR regulation of Inhibitor of differentiation 1 (ID1) is conserved in human BCa cells, and there is a negative correlation between serum 25-hydroxyvitamin D levels and the level of ID1 in primary tumors from patients with BCa.

scholarly journals Chemoprevention Activity of 25-Hydroxyvitamin D in the MMTV-PyMT Mouse Model of Breast Cancer

2014 ◽  
Vol 8 (2) ◽  
pp. 120-128 ◽  
Author(s):  
Lionel Rossdeutscher ◽  
Jiarong Li ◽  
Aimée-Lee Luco ◽  
Ibtihal Fadhil ◽  
Benoit Ochietti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals The Relationship of 25-Hydroxyvitamin D Plasma Levels with Breast Cancer Stadium Assessed from Menopause Status

2021 ◽  
Vol 3 (1) ◽  
pp. 65-72
Author(s):  
Ika Waraztuty ◽  
Astrid Siska Pratiwi ◽  
Melya Susanti ◽  
Ira Astuti ◽  
Zakirullah
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Plasma Levels ◽  
Menopausal Status ◽  
Observational Research ◽  
Cancer Stage ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Post Menopausal ◽  
The Relationship

Breast cancer is a type of cancer with high incidence and mortality especially in developing countries. Vitamin D regulates the expression a number of genes involved in the development of cancer cells. The aim of this study is to analyze the relationship between 25-hydroxyvitamin D (25 (OH) D) plasma level with breast cancer stage based on menopausal status. This is an observational research method with cross sectional design. Research subjects were 53 newly diagnosed breast cancer patients and had not received chemotherapy. Menopausal status and stage data were obtained from interviews and medical record data. Levels of 25-hydroxyvitamin D plasma were measured (ELISA) method. The results obtained Stage II, III and IV each have an average level of vitamin D of 28,56 ng/ml (95% CI; 23,61 – 33,52 ng/ml),  28,18 ng/ml (95% CI: 24,49 – 31,87 ng/ml) and  27,86 ng/ml  (95% CI: 22,68 – 33,04 ng/ml).The average plasma concentration of 25 (OH) D in pre-menopausal patients is 28,54 ng/ml and average plasma 25 (OH) D levels in post-menopausal patients is 27,79 ng/ml. There was no significant relationship between plasma levels of 25 (OH) D and breast cancer stage in both pre-menopausal and post-menopausal patients.

scholarly journals Association of 25-hydroxyvitamin D, Cyclooxygenase-2 and Prostaglandin E2 Serum Levels in Breast Cancer Patients

2021 ◽  
Vol 13 (4) ◽  
pp. 426-32
Author(s):  
Theresia Ilyan ◽  
Dwi Retnoningrum ◽  
Meita Hendrianingtyas ◽  
Dian Widyaningrum ◽  
Banundari Rachmawati
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Serum Level ◽  
Prostaglandin E2 ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Cyclooxygenase 2 ◽  
Hydroxyvitamin D ◽  
Serum Vitamin D ◽  
25 Hydroxyvitamin D

BACKGROUND: Serum levels of 25-hydroxyvitamin D (25(OH)D), prostaglandin E2 (PGE2), and cyclooxygenase 2 (COX2) expression differ between breast cancer stages. Since, previous studies showed mixed results, in this study, we aimed to analyze vitamin D levels related to breast cancer stages and serum levels of COX2 and PGE2 in Indonesia.METHODS: This was a cross sectional study involving 75 breast cancer patients. Subjects were divided into 3 groups, namely operable early stage (K1), locally advanced stage (K2), and advanced stage (K3). Venous blood samples were taken from each subject, then were analyzed for the 25(OH)D, COX2, and PGE2 serum levels by enzyme-linked immunosorbent assay (ELISA) method.RESULTS: There were significant differences in 25(OH)D among groups (p=0.012); between K1 and K2 (p=0.009) and between K1 and K3 (p=0.023). However, there was no significant difference in serum COX2 level (p=0.328). There were significant differences of PGE2 among groups (p=0.002); between K1 and K2 (p=0.036) and between K1 and K3 (p=0.001). Correlation test showed that there were differences between 25(OH)D serum levels and PGE2 serum level (r=0.306, p=0.008) and also between 25(OH)D serum level and breast cancer stage (r=-0.229; p=0.048).CONCLUSION: There were differences in serum Vitamin D and PGE2 levels at various stages of breast cancer. Serum 25(OH)D levels had weak correlation with breast cancer stage and PGE2 serum level. Serum vitamin D level in advanced breast cancer were lower than early stage breast cancer and indicate a poor prognosis.KEYWORDS: breast cancer, 25-hydroxyvitamin D, cyclooxygenase 2, prostaglandin E2

scholarly journals Role of Vitamin D in Preeclampsia

2021 ◽  
Author(s):  
Simmi Kharb
Keyword(s):  
Vitamin D ◽  
Immune Dysfunction ◽  
Vitamin D Supplementation ◽  
Vitamin D Status ◽  
Infant Outcomes ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Vitamin D Signaling ◽  
Maternal And Infant Outcomes

Pathogenesis of preeclampsia involves immune dysfunction, placental implantation, abnormal angiogenesis, excessive inflammation, hypertension that may be affected by vitamin D. Human placenta expresses all the components for vitamin D signaling: Vitamin D receptor (VDR), retinoid X receptor (RXR), 1-alpha- hydroxylase (CYP27B1) and 24- hydroxylase (CYP24A1). Vitamin D binding protein plays a role in binding and transportation of 25 hydroxyvitamin D [25(OH)D] and 1,25(OH)2D3. Vitamin D is activated by 25-hydroxylase (CYP2R1) and 1-alpha -hydroxylase (CYP27B1) and is degraded by 24-hydroxylase (CYP24A1). Vitamin D supplementation is not recommended by WHO for pregnant women and allows recommended nutrient intake (RNI) of 200 IU (5 μg) per day. Further research requires serum 25(OH)D analysis and assessment of maternal and infant outcomes; pre-conceptional vitamin D status.

Serum 25-Hydroxyvitamin D and the risk of breast cancer in women from Southern Morocco: A case-control study

2022 ◽  
pp. 1-8
Author(s):  
Abdellah Moukal ◽  
Abdallah El Farouqi ◽  
Mohamed Aghrouch ◽  
Smail Chadli ◽  
Abderrahmane Zekhnini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Odds Ratio ◽  
Hypovitaminosis D ◽  
Anthropometric Parameters ◽  
Luminal B ◽  
Hydroxyvitamin D ◽  
25 Hydroxy Vitamin D ◽  
25 Hydroxyvitamin D ◽  
Moroccan Women

OBJECTIVES: Assessing Vitamin-D status and checking if low serum 25(OH)D is a factor in breast cancer (BC) for Southern Moroccan women. MATERIALS/METHODS: Study conducted in Morocco about women with BC (n = 90) and controls (n = 90). 25-hydroxy-vitamin-D Biological analyzes executed during the first consultation. Social data and anthropometric parameters were collected for all participants. RESULTS: These women constituted 67.78 % for the cases and 85.6% for the controls. The average age was 48.72±9.71 (cases) and 46.40±12.52 (controls). We found that 53.33% of cases and 40% of controls were postmenopausal and that hypovitaminosis-D affected 80 and 64.4% of cases and controls, respectively. Statistical analysis showed that hypovitaminosis-D was a significative risk factor for BC in Southern Moroccan women. The Odds Ratio was of 5 (p <  0.0001). The BC subtypes had Odds Ratios greater than 1. The highest value was obtained with Luminal B subtype (Odds ratio = 6.25; p = 0.0007). CONCLUSION: This study reinforces the evidence implicating hypovitaminosis-D among modifiable risk factors for BC. Further studies are needed to assess the extent of hypovitaminosis-D in Moroccan women with BC.

scholarly journals Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses’ Health Study II

2014 ◽  
Vol 25 (7) ◽  
pp. 819-827 ◽  
Author(s):  
Jun Wang ◽  
A. Heather Eliassen ◽  
Donna Spiegelman ◽  
Walter C. Willett ◽  
Susan E. Hankinson
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Binding Protein ◽  
Health Study ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Indeks massa tubuh, asupan vitamin D, dan serum 25-hydroxyvitamin D pada pasien kanker payudara

2017 ◽  
Vol 14 (2) ◽  
pp. 56
Author(s):  
Amilia Yuni Damayanti ◽  
Dono Indarto ◽  
Brian Wasita ◽  
Tonang Dwi Ardyanto
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Research Subjects ◽  
Vitamin D Metabolism ◽  
Cross Sectional ◽  
Hydroxyvitamin D ◽  
Vitamin D Intake ◽  
25 Hydroxyvitamin D

Background: Breast cancer is the most common malignancy in women in the world. Vitamin D helps control the majority of gene expression in female reproductive tissues. Body mass index (BMI) influences the bioavailability of vitamin D. Diet is one of the main sources of vitamin D and it is directly converted into 25-hydroxyvitamin D [25 (OH) D] in the liver.Objective: This study aimed to analyze the relationship between BMI and vitamin D intake and 25 (OH)D serum in patients with breast cancer.Method: Analytic observational with cross sectional design was used in this study. A total of 37 breast cancer patient visited Dr. Moewardi Hospital in Surakarta was selected as research subjects using a purposive sampling technique. BMI data was obtained by measuring body weight and height. Vitamin D intake was determined using 1 x 24-hour food recall and semi-quantitative food frequency questionnaire. While, 25(OH)D serum was measured using enzyme-linked immunoabsorbent assay. Data analysis used Spearman correlation test.Results: The averages of BMI, vitamin D intake and 25(OH)D serum of breast cancer patients were 21.96±3.63 kg/m², 3.50±3.30 µg/day and 16.01±14.67 ng/mL respectively. Most breast cancer patients had less vitamin D intake and 25(OH)D serum deficiency. There was a weak relationship between BMI (r=0.188, p=0.266) and vitamin D (r=0.113, p=0.507) and 25 (OH)D serum in breast cancer patients.Conclusion: There were no significant correlations between BMI and vitamin D intake with 25(OH)D serum in breast cancer patients. Further study is required on the effect of chemotherapy regimens on vitamin D metabolism.

Sign in / Sign up

Export Citation Format

Share Document